文献速递眼底病与葡萄膜炎

玻璃体内西罗莫司治疗非感染性后节葡萄膜炎的疗效与安全性:SAKURA项目结果

Efficacy and Safety of Intravitreal Sirolimus for Noninfectious Uveitis of the Posterior Segment: Results from the Sirolimus Study Assessing Double-Masked Uveitis Treatment (SAKURA) Program.
PubMed 文献 · Ophthalmology · 2020-04-03

SAKURA项目合并分析两项3期随机双盲研究,纳入592例活动性非感染性后节葡萄膜炎患者,比较玻璃体内西罗莫司44μg、440μg和880μg的疗效与安全性。440μg组在月5达到玻璃体混浊0级的比例显著高于44μg组(21.2% vs 13.5%,P=0.038),两组最佳矫正视力稳定或改善比例均约80%,且对眼压影响极小。

要点

  • 440μg组月5玻璃体混浊0级比例显著高于44μg组(21.2% vs 13.5%,P=0.038)。
  • 440μg与44μg组最佳矫正视力稳定或改善>5字母比例分别为80.1%和80.2%。
  • 两种剂量总体耐受良好,各访视眼压较基线平均变化极小。

核心结论

  • 玻璃体内西罗莫司440μg较44μg更能改善玻璃体混浊,且对眼压影响小并保持最佳矫正视力。

研究设计与样本

  • 两项3期随机双盲跨国6个月研究的合并分析,共592例活动性非感染性后节葡萄膜炎成人患者随机接受44μg(n=208)、440μg(n=208)或880μg(n=177)玻璃体内西罗莫司,于第1、60、120天给药。

主要发现

  • 440μg组月5玻璃体混浊0级比例显著高于44μg组(21.2% vs 13.5%,P=0.038)。
  • 440μg组月5玻璃体混浊0或0.5+比例显著高于44μg组(50.0% vs 40.4%,P=0.049)。
  • 440μg和44μg组最佳矫正视力稳定(绝对变化<5 ETDRS字母)或改善>5字母的比例分别为80.1%和80.2%。
  • 月5激素逐渐减量成功比例在440μg和44μg组分别为69.6%和68.8%,其中达到玻璃体混浊0或0.5+的比例分别为43.5%和28.1%。
  • 两种剂量总体耐受良好,各分析访视研究眼眼压较基线平均变化极小。

关键数值与推荐

  • 活动性非感染性后节葡萄膜炎定义为中间葡萄膜炎、后葡萄膜炎或全葡萄膜炎,且改良SUN分级玻璃体混浊≥1.5+。
  • 主要疗效终点为月5研究眼玻璃体混浊0级且未使用挽救治疗的患者百分比。

临床怎么用

  • 对于活动性非感染性后节葡萄膜炎,玻璃体内西罗莫司440μg可改善玻璃体混浊并保持视力,且对眼压影响小。

局限性

  • 880μg组因中期分析显示与440μg剂量疗效无显著差异而终止入组。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To evaluate the efficacy and safety of intravitreal sirolimus in the management of noninfectious uveitis of the posterior segment (NIU-PS). DESIGN: Combined analysis of 2 phase 3, randomized, double-masked, multinational, 6-month studies. PARTICIPANTS: Adults with active NIU-PS (intermediate uveitis, posterior uveitis, or panuveitis; defined as vitreous haze [VH] ≥1.5+ on modified Standardization of Uveitis Nomenclature scale). METHODS: Patients were randomized 1:1:1 to receive intravitreal sirolimus 44 μg (n = 208), 440 μg (n = 208), or 880 μg (n = 177) on days 1, 60, and 120. Patients discontinued medications for NIU-PS except for systemic corticosteroids, which were tapered according to protocol. Enrollment in the 880-μg group was terminated after interim results found no significant difference in efficacy compared with the 440-μg dose. MAIN OUTCOME MEASURES: The primary efficacy end point was the percentage of patients with VH of 0 at month 5 in the study eye without the use of rescue therapy. Secondary efficacy end points included VH of 0 or 0.5+, corticosteroid-tapering success, and changes in best-corrected visual acuity (BCVA). Safety measures included ocular and nonocular adverse events. RESULTS: A total of 592 patients were randomized. Significantly higher proportions of patients treated with 440 μg compared with 44 μg intravitreal sirolimus achieved VH of 0 (21.2% vs. 13.5%; P = 0.038) and VH of 0 or 0.5+ (50.0% vs. 40.4%; P = 0.049) at month 5. Best-corrected visual acuity was stable (absolute change <5 ETDRS letters) or improved >5 letters in 80.1% and 80.2% of patients in the 440-μg and 44-μg groups, respectively. At month 5, corticosteroids were tapered successfully in 69.6% and 68.8% of patients in the 440-μg and 44-μg groups, and among these patients, VH of 0 or 0.5+ was achieved by 43.5% and 28.1% in the 440-μg and 44-μg groups. Both doses were generally well tolerated. Mean changes from baseline intraocular pressure (IOP) in the study eye at each analysis visit were minimal in all treatment groups. CONCLUSIONS: Intravitreal sirolimus 440 μg improved ocular inflammation, as measured by VH, compared with the 44-μg dose, with minimal impact on IOP, while preserving BCVA.

来源:Ophthalmology,查看原文。版权归原作者所有。

引用

  1. Merrill PT, Clark WL, Banker AS, et al. Efficacy and Safety of Intravitreal Sirolimus for Noninfectious Uveitis of the Posterior Segment: Results from the Sirolimus Study Assessing Double-Masked Uveitis Treatment (SAKURA) Program. Ophthalmology. 2020. PMID: 32564920. doi:10.1016/j.ophtha.2020.03.033

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。